DK1586319T3 - Thiadiazolidinoner som GSK-3-inhibitorer - Google Patents

Thiadiazolidinoner som GSK-3-inhibitorer

Info

Publication number
DK1586319T3
DK1586319T3 DK05075779.8T DK05075779T DK1586319T3 DK 1586319 T3 DK1586319 T3 DK 1586319T3 DK 05075779 T DK05075779 T DK 05075779T DK 1586319 T3 DK1586319 T3 DK 1586319T3
Authority
DK
Denmark
Prior art keywords
thiadiazolidinones
gsk
inhibitors
Prior art date
Application number
DK05075779.8T
Other languages
English (en)
Inventor
Gil Martinez
Diaz Isabel Dorronsoro
Cascon Mercedes Alonso
Pliego Gema Panizodel
Huerta Ana Fuertes
Puerto Maria Jose Perez
Padilla Miguel Medina
Original Assignee
Noscira Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1586319(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noscira Sa filed Critical Noscira Sa
Application granted granted Critical
Publication of DK1586319T3 publication Critical patent/DK1586319T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
DK05075779.8T 2004-04-05 2005-04-04 Thiadiazolidinoner som GSK-3-inhibitorer DK1586319T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04075997A EP1586318A1 (en) 2004-04-05 2004-04-05 Thiadiazolidinones as GSK-3 inhibitors

Publications (1)

Publication Number Publication Date
DK1586319T3 true DK1586319T3 (da) 2010-02-08

Family

ID=34928129

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05075779.8T DK1586319T3 (da) 2004-04-05 2005-04-04 Thiadiazolidinoner som GSK-3-inhibitorer

Country Status (30)

Country Link
US (2) US7531561B2 (da)
EP (2) EP1586318A1 (da)
JP (1) JP4995076B2 (da)
KR (1) KR101151647B1 (da)
CN (1) CN1946398B (da)
AR (2) AR048820A1 (da)
AT (1) ATE446090T1 (da)
AU (1) AU2005230392B2 (da)
BR (1) BRPI0508788A (da)
CA (1) CA2559740C (da)
CY (1) CY1109724T1 (da)
DE (1) DE602005017215D1 (da)
DK (1) DK1586319T3 (da)
EC (1) ECSP066858A (da)
ES (1) ES2335505T3 (da)
HK (1) HK1100426A1 (da)
HR (1) HRP20100032T1 (da)
IL (1) IL178125A (da)
MA (1) MA28515B1 (da)
MX (1) MXPA06011194A (da)
NO (1) NO332751B1 (da)
NZ (1) NZ549904A (da)
PL (1) PL1586319T3 (da)
PT (1) PT1586319E (da)
RS (1) RS51340B (da)
RU (1) RU2379300C2 (da)
SI (1) SI1586319T1 (da)
TW (1) TWI352084B (da)
WO (1) WO2005097117A1 (da)
ZA (1) ZA200608221B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296087B6 (cs) 2000-05-11 2006-01-11 Consejo Superior Investigaciones Cientificas Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
ES2258406B1 (es) * 2005-02-10 2007-12-01 Neuropharma, S.A. Uso de compuestos heterociclicos como agentes neurogenicos.
EP1749523A1 (en) * 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
EP2043633B1 (en) * 2006-07-18 2016-07-06 University of Rochester Thiadiazolidinone derivatives for treating cancer
WO2008012031A2 (en) * 2006-07-25 2008-01-31 Universität Bern Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
ES2445791T3 (es) 2006-10-21 2014-03-05 Abbvie Deutschland Gmbh & Co Kg Compuestos hetererocíclicos y su uso como inhibidores de la glucógeno sintasa cinasa 3
KR100829468B1 (ko) * 2007-01-17 2008-05-16 한국화학연구원 신규한 1,2,4-티아다이아졸리딘-3,5-다이온 화합물 및 이의제조방법
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2621914B1 (en) 2010-09-27 2016-12-28 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012065065A1 (en) * 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
WO2012078649A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8865750B2 (en) 2011-04-28 2014-10-21 The Regents Of The University Of Michigan Small molecule inhibitors of RGS proteins
EP2527323A1 (en) 2011-05-24 2012-11-28 Noscira, S.A. Urea carbonyl disulfide derivatives and their therapeutic uses
WO2012170657A1 (en) * 2011-06-07 2012-12-13 Georgetown University Targeting gsk-3beta for the treatment of parkinson's disease
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT2838888T (pt) 2012-02-24 2017-07-18 Asd Therapeutics Partners Llc Tiadiazolidinedionas como inibidores da gsk-3
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
CN103992313A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和用途
WO2015075051A1 (en) 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
ES2960601T3 (es) 2014-06-12 2024-03-05 Cedars Sinai Medical Center Composiciones y métodos para el tratamiento del cáncer
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
CA3017341A1 (en) * 2016-03-10 2017-09-14 Alma Mater Studiorum - Universita Di Bologna Treatment of cdkl5 disorders with gsk3.beta. inhibitor tideglusib
GB201617820D0 (en) * 2016-10-21 2016-12-07 King S College London Dental treatment
WO2018226721A1 (en) * 2017-06-06 2018-12-13 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus using a gsk-3 inhibitor
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113827592B (zh) * 2020-06-24 2024-06-18 中国科学院上海药物研究所 一种噻二唑烷二酮基化合物在治疗致病性感染中的应用
WO2022182699A1 (en) 2021-02-24 2022-09-01 Teva Pharmaceuticals International Gmbh Solid state forms of tideglusib and process for preparation thereof
CA3219537A1 (en) 2021-05-21 2022-11-24 Michael Snape Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (en) 2021-05-24 2022-11-30 Consejo Superior De Investigaciones Científicas Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
CN115197167B (zh) * 2022-07-22 2023-07-28 中国药科大学 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用
CN117986202B (zh) * 2024-04-03 2024-06-14 中国药科大学 具有ptpn2抑制活性的1，2，4-噻二唑烷-3，5-二酮化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ296087B6 (cs) * 2000-05-11 2006-01-11 Consejo Superior Investigaciones Cientificas Farmaceutický prostredek pro lécbu nemoci, na nízse podílí heterocyklické inhibitory glykogensyntázakinázy GSK-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
KR101151647B1 (ko) 2012-06-08
MXPA06011194A (es) 2007-03-21
AU2005230392B2 (en) 2011-03-24
PT1586319E (pt) 2010-01-21
BRPI0508788A (pt) 2007-09-04
US20090233971A1 (en) 2009-09-17
AR104417A2 (es) 2017-07-19
NO332751B1 (no) 2013-01-07
EP1586318A1 (en) 2005-10-19
MA28515B1 (fr) 2007-04-03
CA2559740A1 (en) 2005-10-20
NO20064456L (no) 2006-10-02
ZA200608221B (en) 2008-08-27
PL1586319T3 (pl) 2010-06-30
US20050222220A1 (en) 2005-10-06
JP2007531782A (ja) 2007-11-08
CY1109724T1 (el) 2014-08-13
ECSP066858A (es) 2007-01-26
TWI352084B (en) 2011-11-11
RU2006139030A (ru) 2008-05-20
DE602005017215D1 (de) 2009-12-03
AU2005230392A1 (en) 2005-10-20
IL178125A (en) 2012-01-31
AR048820A1 (es) 2006-05-31
TW200538119A (en) 2005-12-01
US8158661B2 (en) 2012-04-17
US7531561B2 (en) 2009-05-12
ATE446090T1 (de) 2009-11-15
WO2005097117A1 (en) 2005-10-20
SI1586319T1 (sl) 2010-02-26
EP1586319B1 (en) 2009-10-21
HRP20100032T1 (hr) 2010-03-31
CN1946398B (zh) 2011-03-30
KR20060131976A (ko) 2006-12-20
HK1100426A1 (en) 2007-09-21
IL178125A0 (en) 2006-12-31
CA2559740C (en) 2014-06-10
CN1946398A (zh) 2007-04-11
RS51340B (en) 2011-02-28
NZ549904A (en) 2010-08-27
ES2335505T3 (es) 2010-03-29
JP4995076B2 (ja) 2012-08-08
EP1586319A1 (en) 2005-10-19
RU2379300C2 (ru) 2010-01-20

Similar Documents

Publication Publication Date Title
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
DK2253614T3 (da) IAP-inhibitorer
DK1778718T3 (da) Iap-inhibitorer
DK1960352T3 (da) 2-adamantylurinstof-derivater som selektive 11beta-hsd1 inhibitorer
NO20161397A1 (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer
DK1934236T3 (da) Heterobifunktionelle pan-selektininhibitorer
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
ATE493403T1 (de) Kinaseinhibitoren
DK2066662T3 (da) Serinhydrolaseinhibitorer
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
ATE418545T1 (de) Nnrt-inhibitoren
DK2067854T3 (da) Kloningsvektorer
DK1713805T3 (da) Kinaseinhibitorer
SE0400476L (sv) Komponent
DE502005004695D1 (de) Sicherheitsfangseil
DK1799707T3 (da) Rekombineret Kunitztypeinhibitor